<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00266123</url>
  </required_header>
  <id_info>
    <org_study_id>0468H1-101497</org_study_id>
    <nct_id>NCT00266123</nct_id>
  </id_info>
  <brief_title>Study Comparing Two Sirolimus Regimens vs. Tacrolimus and Mycophenolate Mofetil Regimen in Kidney Transplant Recipients</brief_title>
  <official_title>A Randomized Open-Label Study to Compare the Safety and Efficacy of Two Different Sirolimus Regimens With a Tacrolimus + Mycophenolate Mofetil Regimen in De Novo Renal Allograft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      To demonstrate the superiority of SRL + TAC elimination + corticosteroids (Group I) and SRL +&#xD;
      MMF + corticosteroids (Group II) to TAC + MMF + corticosteroids (Group III) with respect to&#xD;
      renal allograft function at month 12 post-transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kidney function at 52 weeks after transplantation.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney function at 26, 78 and 104 weeks after transplantation</measure>
  </secondary_outcome>
  <enrollment>420</enrollment>
  <condition>Graft Rejection</condition>
  <condition>Kidney Failure</condition>
  <condition>Kidney Transplant</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  End-stage renal disease with subjects scheduled to receive a primary or secondary&#xD;
             renal allograft from a cadaveric donor, from a living-unrelated mismatched donor, or&#xD;
             from a living-related mismatched donor. Unreported HLA values will be considered a&#xD;
             match.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test before&#xD;
             administration of assigned treatment and agree to use a medically acceptable method of&#xD;
             contraception throughout the treatment period and for 3 months following&#xD;
             discontinuation of assigned treatment.&#xD;
&#xD;
        Other inclusions apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of active systemic or localized major infection.&#xD;
&#xD;
          -  Known hypersensitivity to SRL or its derivatives, macrolide antibiotics,&#xD;
             corticosteroids, TAC or MMF.&#xD;
&#xD;
          -  Multiple organ transplants (i.e., prior or concurrent transplantation of any organs&#xD;
             other than renal transplant).&#xD;
&#xD;
        Other exclusions apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth Reseach</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Belgium, trials-BEL@wyeth.com</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For France, infomedfrance@wyeth.com</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Germany, MedinfoDEU@wyeth.com</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Italy, decresg@wyeth.com</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Poland, WPWZMED@wyeth.com</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Spain, infomed@wyeth.com</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Switzerland, med@wyeth.com</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For United Kingdom, ukmedinfo@wyeth.com</affiliation>
  </overall_official>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>December 14, 2005</study_first_submitted>
  <study_first_submitted_qc>December 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2005</study_first_posted>
  <last_update_submitted>December 18, 2007</last_update_submitted>
  <last_update_submitted_qc>December 18, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 27, 2007</last_update_posted>
  <keyword>Kidney Failure</keyword>
  <keyword>Kidney Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

